[June 20, 2016]

Global Cancer Drug News Issue 2016 - Oncology Performance Validates Strong Focus - Research and Markets

Research and Markets has announced the addition of the "Cancer Drug News Issue 667" report to their offering.

Within Novartis' lacklustre FY2015 results, oncology provided a bright spot. We expect the franchise to feel the effects of Glivec/Gleevec genericisation starting this year, but GlaxoSmithKline-originated products and new launches should bolster the division in the mid-term. Long-term growth will rely on Novartis' multi-faceted approach to developing cancer therapies based on emerging areas of cancer biology.

Key Topics Covered:

Breast Cancer

• Immunomedics' Sacituzumab Govitecan Gains FDA Breakthrough Therapy Designation For TNBC

Haematological Cancer

• Direct Jakafi ompetition Prospects In Myelofibrosis Waning
• Seattle Receives Adcetris Milestone Payment From Takeda
• ST Asia To Distribute PharmaMar's Aplidin In Asia-Pacific

• OSE Pharma Initiates US Phase III Study Of Tedopi In NSCLC
• Tagrisso Approved In EU

Gynaecological Cancer

• ImmunoGen/Merck Enter Clinical Research Collaboration In OC
• TapImmune Granted Fast Track Designation For Lead Cancer Vaccine

Head and Neck Cancer

• Opdivo Phase III SCCHN Trial Stopped Early Following Favourable Results

General Developments

• MedinCell/Sandoz Collaborate To Develop Long-Acting Injectable Products
• GSK Making Gains In Customising Novel Oncology Division
• Mersana/Takeda Expand ACD Partnership
• Eagle Launches Alcohol-Free Docetaxel

Corporate Activity

• AstraZeneca Completes Majority Equity Stake Purchase Of Acerta
• NGS Portfolio Development To Benefit Diagnostics And Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/gg6zxd/cancer_drug_news

View source version on businesswire.com: http://www.businesswire.com/news/home/20160620006024/en/

[ Back To TMCnet.com's Homepage ]